Orenitram ER (Treprostinil Diolamine) Patent Expiration, LOE Window & CMS Spending
Orenitram ER (Treprostinil Diolamine) by United Therapeutics: FDA Orange Book core substance LOE 2028-12-15 (last listed 2031-08-11), 0 AB generics, $305.8M 2024 CMS Part D & Medicaid spend, and 25 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | United Therapeutics |
| FDA Application & Pathway | N203496 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2028-12-15 |
| Last Listed Patent or Exclusivity Date | 2031-08-11 |
| Orange Book Patents (*PED Extensions) | 7 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $305.8M |
| 2024 Medicare Part D Spend | $230.4M |
| 2024 Medicaid Spend | $75.4M |
| Reported Wholesale Price Change (CA SB 17) | 25 WAC filings (max 19.9% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for United Therapeutics across sibling Meru public-data platforms.